Comparing imaging techniques for diagnosing gastric cancer
Official title: Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer
Run by Hunan Cancer Hospital · NCT06543108 · Data updated 2026-11-12
This study is testing if a new type of imaging combined with blood tests can better diagnose gastric cancer and its spread in patients already diagnosed with the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Hunan Cancer Hospital Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Status | Recruiting |
| Started | January 1, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2028 |
| Registry record updated | August 7, 2024 |
| Trial ID | NCT06543108 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old who have been diagnosed with gastric cancer and can undergo the required imaging procedures.
✕Probably not a fit
Patients with a history of other malignant tumors or severe underlying health conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to analyze the diagnostic efficacy of 18F-FAPI-04 PET/CT imaging combined with serum tumor markers in gastric cancer. It will evaluate the effectiveness of both PET/CT and PET/MR imaging in assessing peritoneal metastasis and construct a molecular imaging diagnostic model for gastric cancer. The study will involve patients diagnosed with gastric cancer who will undergo imaging and tumor marker testing within a specified timeframe.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of gastric cancer diagnosis and staging, leading to better treatment outcomes.
How similar studies have gone: While the specific approach of using 18F-FAPI-04 PET/CT is novel, similar imaging techniques have shown promise in other studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age over 18 years old; 2. Diagnosed as a patient with gastric cancer; 3. Receive FAPI PET/CT and FDG PET/CT imaging within one week; 4. Perform serum tumor marker testing one week before and after scanning Exclusion Criteria: 1. History of other malignant tumors; 2. Patients with severe infections, severe underlying diseases such as heart, kidney, and liver; 3. Patients with contraindications for PET-CT examination, poor physical condition, and inability to tolerate the examination; 4. Patients with unorganized pathology or incomplete clinical data
Where it's running
-
Hunan Cancer hospital
Changsha, Hunan, China Recruiting
Study contacts
- Study coordinator: Hui Ye
- Email: yuxin75831@163.com
- Phone: 86-13755117105
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.